AIM: Platinum-induced toxicity severely impedes successful chemotherapy in lung cancer patients. The nucleotide excision repair (NER) pathway is considered as one of the major factors contributing to platinum effects. Furthermore, genetic variances of the NER pathway influence platinum toxicity. eIF3α, over expressed in many malignancies, is an up-stream gene of NER and could regulate its activity. The purpose of this study was to investigate whether eIF3α polymorphism is associated with severe platinum toxicity in patients with non-small cell lung cancer (NSCLC). METHODS: Two hundred and eighty-two incident NSCLC patients, from three different institutions, were enrolled and followed up. These patients were diagnosed and histologically confirmed with non-small cell lung cancer. All patients accepted platinum based chemotherapy for at least two cycles. Twenty-two SNPs of eIF3α were detected in these patients. RESULTS: eIF3α Arg803Lys C > T polymorphism was associated with cisplatin-induced toxicity in NSCLC patients (P = 0.02, OR = 0.54, 95% CI 0.32, 93). T-carrier subjects presented better tolerance to platinum nephrotoxicity, but poorer tolerance to ototoxicity. CONCLUSION: eIF3α Arg803Lys was associated with platinum toxicity in NSCLC patients and could be considered as a predictor for pretreatment evaluation in lung cancer patients.
AIM: Platinum-induced toxicity severely impedes successful chemotherapy in lung cancerpatients. The nucleotide excision repair (NER) pathway is considered as one of the major factors contributing to platinum effects. Furthermore, genetic variances of the NER pathway influence platinumtoxicity. eIF3α, over expressed in many malignancies, is an up-stream gene of NER and could regulate its activity. The purpose of this study was to investigate whether eIF3α polymorphism is associated with severe platinumtoxicity in patients with non-small cell lung cancer (NSCLC). METHODS: Two hundred and eighty-two incident NSCLCpatients, from three different institutions, were enrolled and followed up. These patients were diagnosed and histologically confirmed with non-small cell lung cancer. All patients accepted platinum based chemotherapy for at least two cycles. Twenty-two SNPs of eIF3α were detected in these patients. RESULTS: eIF3α Arg803Lys C > T polymorphism was associated with cisplatin-induced toxicity in NSCLCpatients (P = 0.02, OR = 0.54, 95% CI 0.32, 93). T-carrier subjects presented better tolerance to platinumnephrotoxicity, but poorer tolerance to ototoxicity. CONCLUSION: eIF3α Arg803Lys was associated with platinumtoxicity in NSCLCpatients and could be considered as a predictor for pretreatment evaluation in lung cancerpatients.
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Xia Pu; Michelle A T Hildebrandt; Charles Lu; Jie Lin; David J Stewart; Yuanqing Ye; Jian Gu; Margaret R Spitz; Xifeng Wu Journal: Lung Cancer Date: 2010-05-05 Impact factor: 5.705
Authors: Zhicheng Gong; Xiaojing Xu; Ruiying Hou; Yue Guo; Feifeng Sheng; Dongsheng Ouyang; Honghao Zhou; Zhaoqian Liu Journal: Zhong Nan Da Xue Xue Bao Yi Xue Ban Date: 2010-08
Authors: Shirish M Gadgeel; John C Ruckdeschel; Bhaumik B Patel; Antoinette Wozniak; Andre Konski; Manuel Valdivieso; Deborah Hackstock; Wei Chen; Kimberly Belzer; Angelika M Burger; Lauren Marquette; Andrew Turrisi Journal: J Thorac Oncol Date: 2011-05 Impact factor: 15.609
Authors: Albert Ferro; Yoon K Loke; Lionel D Lewis; Andrew Somogyi; Adam F Cohen; James M Ritter Journal: Br J Clin Pharmacol Date: 2014-02 Impact factor: 4.335
Authors: Evangelia Tserga; Tara Nandwani; Niklas K Edvall; Jan Bulla; Poulam Patel; Barbara Canlon; Christopher R Cederroth; David M Baguley Journal: Sci Rep Date: 2019-03-05 Impact factor: 4.379